Manher Joshi - 17 Aug 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Reporting relationship: Chief Medical Officer
Issuer ticker: RYTM
Reported as of: 17 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Aug 2026, 17:35:38 UTC
Prior SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Vander Stoep, attorney-in-fact for Manher Joshi

Key filing fact

Manher Joshi filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 18 Aug 2026.

Key facts

This page summarizes Manher Joshi's Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 18 Aug 2026, 17:35.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001978048 Primary reporting owner

Joshi Manher

Relationship: Chief Medical Officer
Address: C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON
Signature: /s/ Stephen Vander Stoep, attorney-in-fact for Manher Joshi
Signature date: 18 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RYTM transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +50,000
Change %
Price: $0.000000^*
Shares after: 50,000
Date: 17 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $115.44
Footnotes: F1

RYTM transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +25,000
Change %
Price: $0.000000^*
Shares after: 25,000
Date: 17 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $0.000000
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Stock Options vest and become exercisable as to 25% of the total number of shares subject to the option on the first anniversary of the grant date and as to 6.25% of the total number of shares subject to the option upon the Reporting Person's completion of each successive three months of service to the Corporation.

Footnote F2

The Restricted Stock Units vest as to 25% of the Restricted Stock Units on September 1 of each of 2027, 2028, 2029, and 2030, such that the Restricted Stock Units shall be fully vested on September 1, 2030, subject to the Reporting Person continuing in service through each such vesting date.

Footnote F3

The restricted stock units have no expiration date.